Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: An in vitro evaluation

Blood Purification

Volumn 30, Issue 4, 2010, Pages 277-287

  Schepers, Eva ^a   Glorieux, Griet ^a   Dou, Laetitia ^b   Cerini, Claire ^b   Gayrard, Nathalie ^c   Louvet, Loïc ^d   Maugard, Charlotte ^d   Preus, Pierre ^e   Rodriguez Ortiz, Maria ^f   Argiles, Angel ^c   Brunet, Philippe ^b   Cohen, Gerald ^g   Jankowski, Joachim ^e   Jankowski, Vera ^e   Massy, Ziad ^d   Rodriguez, Mariano ^f   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^d UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Chronic kidney disease; Guanidino compounds; SDMA; Uremic toxins; Vascular damage

Indexed keywords

4 GUANIDINOBUTYRIC ACID; 6 N,N' DIMETHYLARGININE; CREATINE; GUANIDINE; GUANIDINE DERIVATIVE; GUANIDINOSUCCINIC ACID; N(G),N(G) DIMETHYLARGININE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CALCIFICATION; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL VIABILITY; CHRONIC KIDNEY DISEASE; CYTOTOXICITY; ENDOTHELIUM CELL; GRANULOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE ACTIVATION; MOLECULE; MONOCYTE; OSTEOCLASTOGENESIS; PARAMETER; PRIORITY JOURNAL; UREMIA;

CALCINOSIS; CARDIOVASCULAR DISEASES; CELL PROLIFERATION; ENDOTHELIAL CELLS; GUANIDINES; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKOCYTES; LYMPHOCYTE ACTIVATION; REACTIVE OXYGEN SPECIES; RECEPTORS, ANTIGEN; RENAL INSUFFICIENCY, CHRONIC; RISK; UREMIA;

EID: 78149456937     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320765     Document Type: Article

References (49)

1. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R: The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28: 478-483.
2. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
3. Dhingra H, Laski ME: Outcomes research in dialysis. Semin Nephrol 2003; 23: 295-305.
4. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
5. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521.
6. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15: 953-960.
7. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: present state of the art. Int J Artif Organs 2001; 24: 695-725.
8. London GM, Marchais SJ, Guerin AP, Metivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005; 14: 525-531.
9. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
10. De Deyn PP, Marescau B, Cuykens JJ, Van Gorp L, Lowenthal A, De Potter WP: Guanidino compounds in serum and cerebrospinal fluid of non-dialyzed patients with renal insufficiency. Clin Chim Acta 1987; 167: 81-88.
11. De Deyn PP, Marescau B, D'Hooge R, Possemiers I, Nagler J, Mahler C: Guanidino compound levels in brain regions of non-dialyzed uremic patients. Neurochem Int 1995; 27: 227-237.
12. De Deyn PP, D'Hooge R, Van Bogaert PP, Marescau B: Endogenous guanidino compounds as uremic neurotoxins. Kidney Int Suppl 2001; 78:S77-S83.
13. Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire NH, De Deyn PP, Vanholder RC: In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004; 65: 2184-2192.
14. Perna AF, Ingrosso D, Satta E, Lombardi C, Galletti P, D'Aniello A, De Santo NG: Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. J Am Soc Nephrol 2004; 15: 2747-2754.
15. Cooke JP: Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109: 1813-1818.
16. Kielstein JT, Tsikas D, Fliser D: Effects of asymmetric dimethylarginine infusion in humans. Eur J Clin Pharmacol 2005; 62: 39-44.
17. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs- Baumann G, Boehm BO, Winkelmann BR, Marz W: Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007; 53: 273-283. (Pubitemid 46338272)
18. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
19. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Böger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.
20. Bode-Böger SM, Scalera F, Kielstein JT, Martens- Lobenhoffer J, Breithardt G, Fobker M, Reinecke H: Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17: 1128-1134.
21. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R: Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 2008; 25: 1429-1435.
22. Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Adeerstam B, Brunet P, Cerinin C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanhyolder R, Horl WH: Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007; 22: 3381-3390.
23. De Deyn P, Marescau B, Lornoy W, Becaus I, Lowenthal A: Guanidino compounds in uraemic dialysed patients. Clin Chim Acta 1986; 157: 143-150.
24. Kang ES, Tevlin MT, Wang YB, Chiang TM, Cardenas R, Myers LK, Acchiardo SR: Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period. Am J Med Sci 1999; 317: 9-21.
25. Marescau B, Nagels G, Possemiers I, De Broe ME, Becaus I, Billiouw JM, Lornoy W, De Deyn PP: Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997; 46: 1024-1031.
26. Tanaka A, Takahashi Y, Mizokuchi M, Shimada N, Koide H: Plasma, urinary, and erythrocyte concentrations of guanidino compounds in patients with chronic renal failure. Ren Fail 1999; 21: 499-514.
27. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy A, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
28. Wengle B, Hellstrom K: Volatile phenols in serum of uraemic patients. Clin Sci 1972; 43: 493-498.
29. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R: p -Cresylsulphate, the main in vivo metabolite of p -cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596.
30. Tepel M, Echelmeyer M, Orie NN, Zidek W: Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. Kidney Int 2000; 58: 867-872. (Pubitemid 30620037)
31. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756.
32. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p -cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451.
33. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87:E10-E17.
34. Mozar A, Haren N, Chasseraud M, Louvet L, Maziere C, Wattel A, Mentaverri R, Morliere P, Kamel S, Brazier M, Maziere JC, Massy ZA: High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol 2008; 215: 47-54.
35. Vanholder R, Abou-Deif O, Argiles A, Baurmeister U, Beige J, Brouckaert P, Brunet P, Cohen G, De Deyn PP, Drueke TB, Fliser D, Glorieux G, Herget-Rosenthal S, Horl WH, Jankowski J, Jorees A, Massy ZA, Mischak H, Perna A, Rodriguez-Poritllo JM, Spasovski G, Stegmayr BG, Stenvinkel P, Thornalley PJ, Wanner C, Wiecek A: The role of EUTox in uremic toxin research. Semin Dial 2009; 22: 323-328.
36. Kemmerich B, Pennington JE: Different calcium and oxidative metabolic responses in human blood monocytes during exposure to various agonists. J Leukoc Biol 1988; 43: 125-132.
37. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337.
38. Zalba G, Fortuno A, Diez J: Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant 2006; 21: 2686-2690.
39. Caimi G, Montana M, Carollo C, Porretto F, Vaccaro F, Canino B, Lo PR: Polymorphonuclear leukocyte integrins in chronic renal failure. Clin Hemorheol Microcirc 2005; 32: 43-49. (Pubitemid 40164159)
40. Fardon NJ, Wilkinson R, Thomas TH: Rapid fusion of granules with neutrophil cell membranes in hypertensive patients may increase vascular damage. Am J Hypertens 2001; 14: 927-933.
41. Ebisawa M, Bochner BS, Georas SN, Schleimer RP: Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1-induced transendothelial migration. J Immunol 1992; 149: 4021-4028.
42. Walker C, Rihs S, Braun RK, Betz S, Bruijnzeel PL: Increased expression of CD11b and functional changes in eosinophils after migration across endothelial cell monolayers. J Immunol 1993; 150: 4061-4071.
43. Kansas GS: Selectins and their ligands: current concepts and controversies. Blood 1996; 88: 3259-3287.
44. Schleiffenbaum B, Spertini O, Tedder TF: Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 1992; 119: 229-238.
45. Dou L, Brunet P, Dignat-George F, Sampol J, Berland Y: Effect of uremia and hemodialysis on soluble L-selectin and leukocyte surface CD11b and L-selectin. Am J Kidney Dis 1998; 31: 67-73.
46. Menaa C, Esser E, Sprague SM: Beta-2-microglobulin stimulates osteoclast formation. Kidney Int 2008; 73: 1275-1281.
47. Eloot S, Torremans A, De Smet R, Marescau B, De Wachter D, De Deyn PP, Lameire N, Verdonck P, Vanholder R: Kinetic behavior of urea is different from that of other watersoluble compounds: the case of the guanidino compounds. Kidney Int 2005; 67: 1566-1575.
48. Eloot S, Torremans A, De Smet R, Marescau B, De Deyn PP, Verdonck P, Vanholder R: Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis 2007; 50: 279-288.
49. Eloot S, Van Biesen W, Dhondt A, De Smet R, Marescau B, De Deyn PP, Verdonck P, Vanholder R: Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis. Nephrol Dial Transplant 2009; 24: 2225-2232.